Targeting cyclooxygenase-2 in human neoplasia: rationale and promise (Q34287766)

1 August 2017

1 reference

title

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise (English)

1 reference

1 August 2017

Andrew J Dannenberg

1

1 reference

PubMed ID

14706335

1 August 2017

Kotha Subbaramaiah

series ordinal

2

1 reference

1 August 2017

1 December 2003

1 reference

1 August 2017

6

1 reference

inferred from page(s)

published in

Cancer Cell

1 reference

1 August 2017

4

1 reference

1 August 2017

6

1 reference

1 August 2017

431-436

1 reference

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

The RNA-binding protein HuR regulates the expression of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Host cyclooxygenase-2 modulates carcinoma growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900310-6

7 January 2021

10.1016/S1535-6108(03)00310-6

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

14706335